Nucs AI Partners with AstraZeneca to Develop AI-Driven Response Prediction for PSMA-Targeted Radioconjugates
Key Insights
Nucs AI (search) announced a collaboration with AstraZeneca to develop AI-driven response prediction models for PSMA (search)-targeted radioconjugates in metastatic prostate cancer (search) research.
The partnership represents one of the first pharmaceutical industry investments exploring predictive image-based AI algorithms with therapeutic radioconjugates (search).
The collaboration aims to advance precision medicine by shifting patient selection from population-level eligibility criteria toward patient-specific response prediction.
Nucs AI (search), an artificial intelligence company developing diagnostic tools and predictive imaging biomarkers for oncology and theranostics, announced a collaboration with AstraZeneca to develop AI-driven response prediction models for PSMA (search)-targeted radioconjugates in metastatic prostate cancer (search) research. The partnership represents one of the first pharmaceutical industry investments exploring the use of predictive image-based AI algorithms with therapeutic radioconjugates (search).
Advancing Precision Medicine in Prostate Cancer
Under the collaboration, Nucs AI (search) will adapt and validate products for emerging radioconjugates in metastatic castration-resistant prostate cancer (search). The work centers on tuning response-prediction models to the specific characteristics of next-generation therapies, drawing on the platform's foundation in Lutetium-based therapy (search) response predictions. By advancing predictive biomarker development in parallel with AstraZeneca, the collaboration positions AI-driven response prediction to mature in step with the therapies it is designed to support.
The collaboration reflects a growing recognition that predictive imaging-based biomarkers may play a meaningful role in how precision oncology therapies are optimized. According to Nijat Ahmadov, CEO of Nucs AI (search), "For Nucs AI, the collaboration with AstraZeneca anchors a broader strategic ambition: building a precision medicine engine, a platform for identifying and developing predictive imaging biomarker models across existing and novel therapies."
Addressing Patient Selection Challenges
A new generation of therapeutics is expanding the options for intervention in advanced cancer (search) across multiple treatment settings. Yet matching individual patients to the therapies most likely to benefit them remains one of oncology's most persistent challenges. Patient selection has historically focused on confirming whether a therapeutic target is present, rather than predicting whether an individual patient will benefit.
Closing that prediction gap is widely seen as the next frontier in precision oncology, shifting patient selection from population-level eligibility criteria toward patient-specific response prediction. Nucs AI (search)'s platform is designed to address this gap directly, with nuclear oncology serving as the natural starting point where imaging-derived biomarkers connect directly to treatment selection.
Comprehensive Platform Development
The collaboration extends Nucs AI (search)'s broader platform work, which includes several specialized tools for therapeutic radioconjugates (search). SelectPSMA was developed for outcome prediction in the context of a Lutetium-based PSMA (search) therapeutic radioconjugate, while DeepPSMA provides whole-body tumor burden quantification on PSMA PET/CT. TrackPSMA offers automated treatment response evaluation capabilities.
Together, these tools form the foundation of the company's growing precision medicine engine for therapeutic radioconjugates (search). Ahmadov emphasized that this approach scales beyond a single therapy class or cancer type, extending over time across additional treatment modalities, disease contexts, and therapeutic targets.